The development of strategies to modulate the activation of the TGF-β/Smads signaling pathway by targeting the IGF2BP3/EMP1/VASP axis may hold promise to improve the current plight of pancreatic cancer. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.